IPP Bureau
IndiaAI, CDSCO launch hackathon to accelerate health innovation approvals
By IPP Bureau - April 08, 2026
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
Transgene and NEC join forces to advance personalized cancer vaccine
By IPP Bureau - April 08, 2026
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
Alpha Cognition secures key US patent for traumatic brain injury treatment
By IPP Bureau - April 08, 2026
The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL
Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health
By IPP Bureau - April 08, 2026
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
WHO updates global guidelines to combat opioid crisis
By IPP Bureau - April 08, 2026
Opioid dependence remains a major driver of death and disease worldwide
OneCyte and Kemp Proteins to revolutionize cell line development
By IPP Bureau - April 08, 2026
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
Moderna to reveal late-breaking data on flu & RSV mRNA vax at ESCMID 2026
By IPP Bureau - April 08, 2026
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion
By IPP Bureau - April 08, 2026
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
ImmunityBio responds to FDA concerns over promotional content
By IPP Bureau - April 08, 2026
Stipple Bio raises $100M Series A to advance next-gen cancer therapies
By IPP Bureau - April 08, 2026
The new capital is expected to fund the company through 2029
Biocon launches denosumab biosimilars Bosaya and Aukelso in US market
By IPP Bureau - April 08, 2026
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Lupin wins USFDA nod for generic Dapagliflozin tablets
By IPP Bureau - April 08, 2026
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Allergan Aesthetics opens cutting-edge AMI training center in Austin
By IPP Bureau - April 08, 2026
The center combines rigorous scientific instruction with practical, hands-on training, equipping providers with the clinical, consultative, and business skills needed to deliver safe, effective, and patient-centered care
Apnimed secures $150 million financing to fuel US launch of oral sleep apnea drug AD109
By IPP Bureau - April 08, 2026
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
